Overview

MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This Phase III clinical trial will examine the safety, tolerability, and efficacy of the addition of MK-0431/ONO-5435 to Japanese patients with Type 2 Diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and rapid-acting insulin secretagogue monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Collaborator:
MSD K.K.
Treatments:
Insulin, Short-Acting
Sitagliptin Phosphate